StockData
Evolus, Inc. logo

Evolus, Inc. (EOLS) stock

EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$6.69+0.06 (+0.90%)

Close on Nov 17, 2026Market cap $441.88MP/E –Yield –

Earnings

Evolus's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 2, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$78.00M
+13.0% on a year earlier
EPS, Q3 FY2026
-$0.19
Latest guidance
Raised
Nov 4, 2026 · 5 items

Quarterly results

Revenue and earnings per share from each of Evolus's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 2, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$78.00M+13.0%-$0.19Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026during market hours$84.10M+21.2%–Release
Q1 FY2026ended Mar 31, 2026May 4, 2026during market hours$73.10M+6.7%–Release
Q4 FY2025ended Dec 31, 2025Mar 3, 2026during market hours$90.30M+14.3%$0.00Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025during market hours$69.00M+12.9%–Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025during market hours$69.40M+3.7%-$0.27Release
Q1 FY2025ended Mar 31, 2025May 7, 2025during market hours$68.50M+15.5%-$0.30Release
Q4 FY2024ended Dec 31, 2024Mar 4, 2025during market hours$79.00M+29.5%-$0.11Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024during market hours$61.10M+22.2%–Release
Q2 FY2024ended Jun 30, 2024Jul 31, 2024during market hours$66.90M+35.7%-$0.18Release
Q1 FY2024ended Mar 31, 2024May 7, 2024during market hours$59.30M+42.2%-$0.22Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Evolus's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
total net revenuesGAAPFY2026$330.00M – $337.00M–NewNov 4, 2026
total net revenuesFY2026$330.00M – $337.00M$327.00M – $337.00MRaisedAug 5, 2026
Total net revenuesFY2026$327.00M – $337.00M–NewMar 3, 2026
adjusted gross profit marginnon-GAAPFY202667% – 67.5%65.5% – 67%RaisedNov 4, 2026
adjusted gross profit marginnon-GAAPFY202667% – 67.5%65.5% – 67%RaisedAug 5, 2026
contribute 10% to 12% of total revenueFY202610% – 12%–NewMar 3, 2026
Evolysse ® and Estyme ® injectable HA gels to contribute 10% to 12% of total revenueFY202610% – 12%–NewAug 5, 2026
non-GAAP operating expensesnon-GAAPFY2026$210.00M – $213.00M$210.00M – $216.00MLoweredNov 4, 2026
non-GAAP operating expensesnon-GAAPFY2026$212.00M – $216.00M$210.00M – $216.00MRaisedAug 5, 2026
compound annual growth rateFY2028+27%–NewMay 7, 2025
total net revenueGAAPFY2028$450.00M – $500.00M$700.00MLoweredNov 4, 2026
total net revenueFY2028$450.00M – $500.00M$450.00M – $500.00MReaffirmedAug 5, 2026
total net revenueFY2028$450.00M – $500.00M$700.00MLoweredMar 3, 2026
non-GAAP operating income marginsnon-GAAPFY202813% – 15%20%LoweredJan 9, 2026
non-GAAP operating income marginsnon-GAAPFY202820%20%ReaffirmedAug 5, 2025
operating marginsFY202820%–NewNov 6, 2024
Adjusted EBITDA marginsnon-GAAPFY202813% – 15%13% – 15%ReaffirmedNov 4, 2026
Adjusted EBITDA marginsnon-GAAPFY202813% – 15%–NewAug 5, 2026
Adjusted EBITDA marginsnon-GAAPFY202813% – 15%–NewMay 4, 2026

Guidance vs results

The last range Evolus gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$295.00M – $305.00M$297.20MΣ4QWithin range
FY2025Revenue growth+11% – +15%+11.6%Σ4QWithin range

Guidance history

Every forecast Evolus put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026Adjusted EBITDA marginsFY202813% – 15%Reaffirmed
Nov 4, 2026adjusted gross profit marginFY202667% – 67.5%Raised
Nov 4, 2026non-GAAP operating expensesFY2026$210.00M – $213.00MLowered
Nov 4, 2026total net revenuesFY2026$330.00M – $337.00MNew
Nov 4, 2026total net revenueFY2028$450.00M – $500.00MLowered
Aug 5, 2026Adjusted EBITDA marginsFY202813% – 15%New
Aug 5, 2026adjusted gross profit marginFY202667% – 67.5%Raised
Aug 5, 2026Evolysse ® and Estyme ® injectable HA gels to contribute 10% to 12% of total revenueFY202610% – 12%New
Aug 5, 2026non-GAAP operating expensesFY2026$212.00M – $216.00MRaised
Aug 5, 2026total net revenuesFY2026$330.00M – $337.00MRaised
Aug 5, 2026total net revenueFY2028$450.00M – $500.00MReaffirmed
May 4, 2026Adjusted gross profit marginFY202665.5% – 67%New
May 4, 2026Non-GAAP operating expensesFY2026$210.00M – $216.00MNew
May 4, 2026Adjusted EBITDA marginsFY202813% – 15%New
May 4, 2026Total net revenuesFY2026$327.00M – $337.00MReaffirmed
May 4, 2026total net revenueFY2028$450.00M – $500.00MReaffirmed
Mar 3, 2026adjusted EBITDA marginsFY202813% – 15%New
Mar 3, 2026adjusted gross profit marginFY202665.5% – 67%New
Mar 3, 2026contribute 10% to 12% of total revenueFY202610% – 12%New
Mar 3, 2026Non-GAAP operating expensesFY2026$210.00M – $216.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Evolus filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Update
  5. Results
  6. Results
  7. Results
  8. Results
  9. Update
  10. Results
  11. Update
  12. Results
  13. Update
  14. Results
  15. Results

See a number that looks wrong?